תבנית:תרופה/אוורל 50 - Evorel 50
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | |
| ×ר××× ×¤×¢×× (ATC5) | *Estradiol AS HEMIHYDRATE 3.2MG âG03CA03
|
| צ×רת ××ª× | TRANSDERMAL |
| צ×רת ××× ×× | PATCHES |
| ×ת×××× | Deficiency symptoms by absence of Estrogen after the menopause or after surgical removal of the ovarians. They comprise hot flushes, insomnia, atrophies of the urogenital system, changes of mood and increasing loss of the bone substance, which can lead to osteoporosis. In women with intact uterus, estrogen substitution must always be supplemented with a sequential gestagen therapy.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/××××¨× 50 - Evorel 50 | |
| ×ת××ת ××× ×× | Posology and method of administration |
| ×ת××××ת × ×× | Contraindications |
| ת×פע×ת ××××× | Undesirable effects |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× | |
| ×¢××× ×צר×× | *×¢××× ×צר×× |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××¨× 50 ® ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | JANSSEN PHARMACEUTICA N.V.,BELGIUM |
| ×©× ××¢× ×ר×ש×× | J-C HEALTH CARE LTD |
| ר×ש××× | ת×ר×× ××ש×: 01/1996. ר×ש××× ×ת×ר××: 11/2011 |
| ת×ר×× ×¢×××× ××ר×× | 14/11/18 |
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: ××××¨× 50 - Evorel 50
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/××××¨× 50 - Evorel 50}}
×:
{{תר×פ×/××××¨× 50 - Evorel 50
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־14 בנובמבר 2018 ב־20:26